Ganetespib shows potency against ALK-positive lung cancer and overcomes crizotinib resistance

A drug that indirectly impairs the function of several cancer-driving proteins, including anaplastic lymphoma kinase (ALK), may be an effective new treatment for patients with ALK—positive non-small cell lung cancer.